Sonnet BioTherapeutics’ (SONN) “Buy” Rating Reiterated at Chardan Capital
Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a research note issued on Friday,Benzinga reports. They presently have a $20.00 price target on the stock. Sonnet BioTherapeutics Price Performance SONN stock opened at $1.31 on Friday. Sonnet BioTherapeutics has a 1 year low of […]
Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a research note issued on Friday,Benzinga reports. They presently have a $20.00 price target on the stock. Sonnet BioTherapeutics Price Performance SONN stock opened at $1.31 on Friday. Sonnet BioTherapeutics has a 1 year low of […]
